-
Something wrong with this record ?
Impact of Long-Term Lithium Treatment on Renal Function in Patients With Bipolar Disorder Based on Novel Biomarkers
M. Dastych, O. Synek, J. Gottwaldová,
Language English Country United States
Document type Journal Article
- MeSH
- Antimanic Agents administration & dosage adverse effects MeSH
- Biomarkers metabolism MeSH
- Bipolar Disorder drug therapy MeSH
- Time Factors MeSH
- Adult MeSH
- Glomerular Filtration Rate MeSH
- Middle Aged MeSH
- Humans MeSH
- Lithium Carbonate administration & dosage adverse effects MeSH
- Kidney Diseases chemically induced epidemiology MeSH
- Aged MeSH
- Kidney Function Tests MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: Lithium in the form of lithium carbonate (Li2CO3) has become one of the most effective and widely prescribed drugs for mood stabilization. However, lithium has adverse effects on renal tubular functions, such as decreased concentrating function of the kidneys, and even occasional symptoms of nephrogenous diabetes insipidus occur with additional evidence of glomerular disruption in lithium-treated patients. METHODS: We assessed the kidney function of patients with bipolar disorder who are under long-term lithium treatment using novel markers of kidney damage such as plasma neutrophil gelatinase-associated lipocalin, cystatin C, albuminuria, estimated glomerular filtration rate, Chronic Kidney Disease-Epidemiology Investigation using creatinine and cystatin C, and serum and urinary osmolality, and compared the results with those of age-matched patients with bipolar disorder not treated with lithium. The study enrolled 120 patients with bipolar disorder, consisting of 80 (30 male and 50 female patients) who have been receiving lithium for 0.5 to 20 (mean, 7) years and 40 (10 male and 30 female patients) who had never been exposed to lithium treatment. RESULTS: Patients treated with lithium had significantly decreased urine osmolality (mean ± SD, 405 ± 164 vs 667 ± 174 mmol/kg) and urine-to-serum osmolality ratio (1.35 ± 0.61 vs 2.25 ± 0.96). No significant difference was found in creatinine, estimated glomerular filtration rate values calculated using the Chronic Kidney Disease-Epidemiology Investigation using creatinine and cystatin C, neutrophil gelatinase-associated lipocalin, cystatin C, and albuminuria between both groups. We found no significant difference in renal biomarkers between patients treated with lithium for 6 to 24 months and those treated for 25 to 240 months. CONCLUSIONS: We found significantly decreased kidney concentrating ability in the long-term lithium-treated patients compared with the control group. Other renal function markers did not indicate any significant signs of renal dysfunction.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19034677
- 003
- CZ-PrNML
- 005
- 20191014102802.0
- 007
- ta
- 008
- 191007s2019 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/JCP.0000000000001030 $2 doi
- 035 __
- $a (PubMed)30932947
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Dastych, Milan
- 245 10
- $a Impact of Long-Term Lithium Treatment on Renal Function in Patients With Bipolar Disorder Based on Novel Biomarkers / $c M. Dastych, O. Synek, J. Gottwaldová,
- 520 9_
- $a BACKGROUND: Lithium in the form of lithium carbonate (Li2CO3) has become one of the most effective and widely prescribed drugs for mood stabilization. However, lithium has adverse effects on renal tubular functions, such as decreased concentrating function of the kidneys, and even occasional symptoms of nephrogenous diabetes insipidus occur with additional evidence of glomerular disruption in lithium-treated patients. METHODS: We assessed the kidney function of patients with bipolar disorder who are under long-term lithium treatment using novel markers of kidney damage such as plasma neutrophil gelatinase-associated lipocalin, cystatin C, albuminuria, estimated glomerular filtration rate, Chronic Kidney Disease-Epidemiology Investigation using creatinine and cystatin C, and serum and urinary osmolality, and compared the results with those of age-matched patients with bipolar disorder not treated with lithium. The study enrolled 120 patients with bipolar disorder, consisting of 80 (30 male and 50 female patients) who have been receiving lithium for 0.5 to 20 (mean, 7) years and 40 (10 male and 30 female patients) who had never been exposed to lithium treatment. RESULTS: Patients treated with lithium had significantly decreased urine osmolality (mean ± SD, 405 ± 164 vs 667 ± 174 mmol/kg) and urine-to-serum osmolality ratio (1.35 ± 0.61 vs 2.25 ± 0.96). No significant difference was found in creatinine, estimated glomerular filtration rate values calculated using the Chronic Kidney Disease-Epidemiology Investigation using creatinine and cystatin C, neutrophil gelatinase-associated lipocalin, cystatin C, and albuminuria between both groups. We found no significant difference in renal biomarkers between patients treated with lithium for 6 to 24 months and those treated for 25 to 240 months. CONCLUSIONS: We found significantly decreased kidney concentrating ability in the long-term lithium-treated patients compared with the control group. Other renal function markers did not indicate any significant signs of renal dysfunction.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a antimanika $x aplikace a dávkování $x škodlivé účinky $7 D018692
- 650 _2
- $a biologické markery $x metabolismus $7 D015415
- 650 _2
- $a bipolární porucha $x farmakoterapie $7 D001714
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a hodnoty glomerulární filtrace $7 D005919
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nemoci ledvin $x chemicky indukované $x epidemiologie $7 D007674
- 650 _2
- $a vyšetření funkce ledvin $7 D007677
- 650 _2
- $a lithiumkarbonát $x aplikace a dávkování $x škodlivé účinky $7 D016651
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a časové faktory $7 D013997
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Synek, Oldřich $u Department of Psychiatry, University Hospital Brno, Faculty of Medicine Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Gottwaldová, Jana
- 773 0_
- $w MED00002603 $t Journal of clinical psychopharmacology $x 1533-712X $g Roč. 39, č. 3 (2019), s. 238-242
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30932947 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20191007 $b ABA008
- 991 __
- $a 20191014103227 $b ABA008
- 999 __
- $a ok $b bmc $g 1451337 $s 1073227
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 39 $c 3 $d 238-242 $e - $i 1533-712X $m Journal of clinical psychopharmacology $n J Clin Psychopharmacol $x MED00002603
- LZP __
- $a Pubmed-20191007